NeoImmuneTech Inc
950220
Company Profile
Business description
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.
Contact
2400 Research Boulevard
Suite 250
RockvilleMD20850
USAT: +1 240 801-9065
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
82
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,137.26 | 86.19 | 1.07% |
| DAX 40 | 22,732.24 | 321.97 | 1.44% |
| Dow JONES (US) | 43,758.96 | 137.80 | 0.32% |
| FTSE 100 | 8,722.03 | 53.36 | 0.62% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,196.80 | 170.41 | 0.90% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,991.45 | 36.20 | 0.61% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |